Estrogen Receptor Variants and Breast Cancer
雌激素受体变异与乳腺癌
基本信息
- 批准号:7048684
- 负责人:
- 金额:$ 26.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-09-01 至 2008-03-31
- 项目状态:已结题
- 来源:
- 关键词:breast neoplasmscell lineestradiolestrogen inhibitorestrogen receptorsgene induction /repressiongene mutationhormone regulation /control mechanismhormone related neoplasm /cancermitogen activated protein kinaseneoplasm /cancer geneticsneoplasm /cancer pharmacologynuclear magnetic resonance spectroscopyphosphatidylinositol 3 kinaseprotein isoformsprotein protein interactionprotein structure functionreceptor bindingsite directed mutagenesissurface plasmon resonanceyeast two hybrid system
项目摘要
DESCRIPTION: (provided by the applicant) Breast cancer is among the most devastating diseases affecting women. The risk for a North American women
getting breast cancer has doubled since 1940, and at present one woman in eight
is at risk of developing the disease. Estrogens play a significant role in the
development of breast cancer. The mitogenic action of estrogen is amplified by
the hormone-dependent transcription factor, estrogen receptor (ER), which
assembles transcription accessory proteins in a ligand dependent manner. This
multifaceted process is largely aided by the ligand-induced conformational
adjustments in the ligandbinding domain (LBD) of ER. However, the contribution
of the neighboring F-domain in this critical stage of ER action is not well
understood. We hypothesize that the F-domain of ERa contributes to the
ligandinduced conformation of the LBD, which determines the recruitment of
comodulators onto ER for its function. In Aim 1, we will focus on the role of
ERa F-domain in the ligand-dependent recruitment of coactivators. We have
designed several approaches to address this issue, which include coactivator
recruitment by F-domain mutants in the absence and presence of chromatin. Aim 2
will measure the consequence of F-domain perturbation on the biological
properties of ERa. In Aim 3, we will employ NMR analysis to address the most
pressing question of whether F-domain affects the overall topology of the LBD.
In the absence of a crystal structure of the E-F domain, our results from this
Aim will, for the first time, shed light on E-F domain's solution structure.
This will greatly aid us in understanding the mechanism of ERa actions. Aim 4
will determine if the F-domain influences the non-genotropic actions of ER. We
expect that a successful completion of our objectives will not only provide a
greater understanding of estrogen receptor actions, but will also provide new
opportunities to develop novel pharmacological compounds to antagonize the
mitogenic actions of estrogens.
描述:(由申请人提供)乳腺癌是最常见的癌症之一。 影响妇女的毁灭性疾病。北美女性面临的风险
自1940年以来,患乳腺癌的人数增加了一倍,目前每八名妇女中就有一名
有患上这种疾病的风险雌激素在这一过程中起着重要的作用。
乳腺癌的发展。雌激素的促有丝分裂作用被放大,
雌激素依赖性转录因子雌激素受体(ER),
以配体依赖性方式组装转录辅助蛋白。这
多方面的过程在很大程度上是由配体诱导的构象
ER配体结合结构域(LBD)的调整。然而,贡献
在ER作用的这个关键阶段,邻近F-结构域的
明白我们假设ER α的F-结构域有助于
LBD的配体诱导构象,其决定了LBD的募集。
为它的功能添加了共调节剂。在目标1中,我们将重点关注
ER α F结构域在辅激活因子的配体依赖性募集中的作用。我们有
设计了几种方法来解决这个问题,其中包括辅活化剂,
在不存在和存在染色质的情况下通过F结构域突变体的募集。目的2
将测量F域扰动对生物的影响
ER a的特性。在目标3中,我们将使用NMR分析来解决最
F域是否影响LBD的整体拓扑结构的紧迫问题。
在缺乏E-F结构域的晶体结构的情况下,我们的结果从这个
Aim将首次揭示E-F域的解结构。
这将极大地帮助我们理解ERa作用的机制。目标4
将确定F-结构域是否影响ER的非遗传性作用。我们
我们期望,成功地完成我们的目标不仅将提供一个
更好地了解雌激素受体的作用,但也将提供新的
开发新的药理学化合物来拮抗
雌激素的促有丝分裂作用。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Environmental estrogens induce transcriptionally active estrogen receptor dimers in yeast: activity potentiated by the coactivator RIP140.
环境雌激素诱导酵母中的转录活性雌激素受体二聚体:共激活因子RIP140增强的活性。
- DOI:10.1289/ehp.0010897
- 发表时间:2000-02
- 期刊:
- 影响因子:10.4
- 作者:Sheeler CQ;Dudley MW;Khan SA
- 通讯作者:Khan SA
The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization.
雌激素受体-α 的 F 结构域抑制配体诱导的受体二聚化。
- DOI:10.1016/j.mce.2008.08.001
- 发表时间:2008
- 期刊:
- 影响因子:4.1
- 作者:Yang,Jun;Singleton,DavidW;Shaughnessy,ElizabethA;Khan,SohaibA
- 通讯作者:Khan,SohaibA
Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action.
- DOI:10.1073/pnas.97.7.3696
- 发表时间:2000-03
- 期刊:
- 影响因子:11.1
- 作者:Mark W. Dudley;Cameron Q. Sheeler;Hong Wang;Sohaib A. Khan
- 通讯作者:Mark W. Dudley;Cameron Q. Sheeler;Hong Wang;Sohaib A. Khan
Estrogen receptor domains E and F: role in dimerization and interaction with coactivator RIP-140.
雌激素受体结构域 E 和 F:在二聚化和与共激活剂 RIP-140 相互作用中的作用。
- DOI:10.1210/mend.13.2.0244
- 发表时间:1999
- 期刊:
- 影响因子:0
- 作者:Peters,GA;Khan,SA
- 通讯作者:Khan,SA
Estrogen receptor variants ERdelta5 and ERdelta7 down-regulate wild-type estrogen receptor activity.
雌激素受体变体 ERdelta5 和 ERdelta7 下调野生型雌激素受体活性。
- DOI:10.1016/s0303-7207(99)00125-2
- 发表时间:1999
- 期刊:
- 影响因子:4.1
- 作者:Wang,H;Zeng,X;Khan,SA
- 通讯作者:Khan,SA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Sohaib A. Khan其他文献
Estrogen receptor variants ERΔ5 and ERΔ7 down-regulate wild-type estrogen receptor activity
雌激素受体变体 ERΔ5 和 ERΔ7 下调野生型雌激素受体活性
- DOI:
- 发表时间:
1999 - 期刊:
- 影响因子:4.1
- 作者:
Hong Wang;Xin Zeng;Sohaib A. Khan - 通讯作者:
Sohaib A. Khan
Progesterone withdrawal and RU-486 treatment stimulate apoptosis in specific uterine decidual cells
黄体酮停药和 RU-486 治疗刺激特定子宫蜕膜细胞凋亡
- DOI:
10.1038/sj.cdd.4400202 - 发表时间:
1997 - 期刊:
- 影响因子:12.4
- 作者:
B. C. Moulton;J. Motz;Cleo Serdoncillo;K. Akcali;Sohaib A. Khan - 通讯作者:
Sohaib A. Khan
Estrogen Receptor and Breast Cancer: A Historical Perspective
雌激素受体和乳腺癌:历史视角
- DOI:
10.1007/978-3-319-99350-8_1 - 发表时间:
2018 - 期刊:
- 影响因子:0
- 作者:
Sohaib A. Khan - 通讯作者:
Sohaib A. Khan
Control of Apoptosis in the Uterus During Decidualization
子宫蜕膜化过程中细胞凋亡的控制
- DOI:
10.1007/978-1-4612-1944-6_5 - 发表时间:
1997 - 期刊:
- 影响因子:4.3
- 作者:
B. C. Moulton;K. Akcali;T. Ogle;T. Brown;J. Motz;Sohaib A. Khan - 通讯作者:
Sohaib A. Khan
Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat (44493)
口服他莫昔芬、托瑞米芬、脱氢表雄酮和伏罗唑对大鼠子宫组织形态学的影响 (44493)
- DOI:
10.1177/153537020022300311 - 发表时间:
2000 - 期刊:
- 影响因子:3.2
- 作者:
K. Nephew;E. Osborne;R. Lubet;C. Grubbs;Sohaib A. Khan - 通讯作者:
Sohaib A. Khan
Sohaib A. Khan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Sohaib A. Khan', 18)}}的其他基金
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 26.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 26.89万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 26.89万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 26.89万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 26.89万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 26.89万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 26.89万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 26.89万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 26.89万 - 项目类别:
Studentship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 26.89万 - 项目类别: